"Arabinofuranosyluracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE.
| Descriptor ID |
D001086
|
| MeSH Number(s) |
D03.383.742.680.852.150 D13.570.065.090 D13.570.685.852.150
|
| Concept/Terms |
Arabinofuranosyluracil- Arabinofuranosyluracil
- Ara-U
- Ara U
- Uracil Arabinoside
- Arabinoside, Uracil
- Arauridine
- Sponguridine
- Uracil Arabinofuranoside
- Arabinofuranoside, Uracil
- 1-beta-D-Arabinofuranosyl Uracil
- 1 beta D Arabinofuranosyl Uracil
- Uracil, 1-beta-D-Arabinofuranosyl
- Arabinosyluracil
|
Below are MeSH descriptors whose meaning is more general than "Arabinofuranosyluracil".
Below are MeSH descriptors whose meaning is more specific than "Arabinofuranosyluracil".
This graph shows the total number of publications written about "Arabinofuranosyluracil" by people in this website by year, and whether "Arabinofuranosyluracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Arabinofuranosyluracil" by people in Profiles.
-
Jones SA, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother. 2013 Sep; 57(9):4181-9.
-
Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, Moxham C, Sorbel J, Snow A, Blum MR, Rousseau F, Marcellin P. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2008 Jun; 27(12):1282-92.
-
Semino-Mora C, Leon-Monzon M, Dalakas MC. Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Lab Invest. 1997 Apr; 76(4):487-95.
-
Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995 May; 1(5):417-22.
-
Soike K, Huang JL, Tu JI, Stouffer B, Mitroka JG, Swerdel M, Olsen S, Bonner DP, Tuomari AV, Field AK. Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys. J Infect Dis. 1992 Apr; 165(4):732-6.
-
Chandrasekaran B, Kute TE, Capizzi RL. Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil. Cancer Chemother Pharmacol. 1992; 29(6):455-60.
-
Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper MR, Dillman R, Major WB, Dupre E, McIntyre OR. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study. J Clin Oncol. 1988 Mar; 6(3):499-508.
-
Capizzi RL, Yang JL, Rathmell JP, White JC, Cheng E, Cheng YC, Kute T. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation. Semin Oncol. 1985 Jun; 12(2 Suppl 3):65-74.
-
Capizzi RL, Yang JL, Cheng E, Bjornsson T, Sahasrabudhe D, Tan RS, Cheng YC. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol. 1983 Dec; 1(12):763-71.